Influenza virus quadrivalent vaccine intranasal - Eurocine Vaccines

Drug Profile

Influenza virus quadrivalent vaccine intranasal - Eurocine Vaccines

Alternative Names: Immunose FLU

Latest Information Update: 25 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eurocine
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Influenza virus infections

Most Recent Events

  • 24 Oct 2016 Eurocine Vaccines initiates enrolment in a phase I/II trial trial for Influenza virus infections (Prevention, In volunteers) in Sweden (NCT02998996)
  • 04 Jul 2016 Eurocine Vaccines files an application to conduct a phase I/II trial with the Medical Products Agency in Sweden for Influenza virus infections
  • 17 May 2016 Eurocine Vaccines has patent protection for Influenza virus vaccine intranasal in Russia, Australia and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top